Loxo Oncology (LOXO) Misses Q4 EPS by 9c

Note: EPS may not be comparable

Loxo Oncology (NASDAQ: LOXO) reported Q4 EPS of ($1.24), $0.09 worse than the analyst estimate of ($1.15). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Loxo Oncology (LOXO) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• XP Inc eyes US banking license as next business step
• L3Harris CEO steps down amid conduct review, shares drop